GET DAILY SIGNALSNovavax (NVAX) Drops -32.7% Over 30 Days: Reading the Recent Pullback
Key Takeaways
- Novavax (NVAX) shares fell roughly 32.7% over the last 30 days, sliding from a closing price near $12.64 to about $8.51 as an early-October rally fully unwound.
- The pullback followed a period in which the stock briefly traded above $13 intraday, underscoring elevated volatility in the shares.
- The quarterly picture is notably different: NVAX is up about 4.5% over the past three months, reflecting broader consolidation in the single-digit-to-low-teens range.
- The move highlights the sentiment-driven nature of vaccine-focused biotech names, where news flow and risk appetite can shift sharply over short periods.
- Investors continue to weigh Novavax's COVID-19 franchise, its COVID-influenza combination vaccine program, and its recombinant nanoparticle platform against a competitive commercialization environment.
- For additional data, explore Novavax's Price Targets, Earnings, and Forecast pages for deeper context and metrics.
- Traders can also explore Trending AI Robots for automated trading strategies across thousands of tickers.
Novavax (NVAX) Company Overview and Market Position
Novavax, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, focused on developing and commercializing vaccines for serious infectious diseases. Its most widely recognized product is a protein-based COVID-19 vaccine built on a recombinant nanoparticle platform and formulated with the company's proprietary Matrix-M adjuvant. Novavax has worked to broaden its portfolio beyond the pandemic, advancing a combination COVID-19 and influenza vaccine candidate as well as a stand-alone influenza program. Investors follow NVAX closely because its financial results remain tied to vaccine demand, seasonal immunization cycles, and the company's progress toward building a sustainable, post-pandemic product pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Novavax (NVAX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NVAX declined roughly 32.7%, moving from a closing price of about $12.64 to near $8.51. The stock touched its highest levels of the period in early October, when it briefly traded above $13 intraday, before a steady retreat through mid-October and into November erased those gains.
The last quarter tells a more nuanced story. From a closing level near $8.14 roughly three months earlier, the stock rallied into the low-to-mid teens and then pulled back, finishing about 4.5% higher over the period. In other words, the sharp 30-day decline largely reversed a short-lived surge rather than marking a fresh breakdown from a longer-term uptrend.
What Drove NVAX Stock Price in the Last 30 Days
The 30-day decline primarily reflects the unwinding of an early-October surge. After climbing from the single digits to an intraday high above $13, the shares gave back nearly all of that move in a matter of weeks, a pattern consistent with profit-taking and fading momentum rather than a single company-specific event.
The reversal also coincided with broader risk-off conditions in speculative biotech, where valuation-sensitive names often lose ground when investor sentiment cools. Without a clearly identifiable corporate catalyst driving the move, the price action appears to have been led by positioning and sector rotation, with elevated trading volume on down days pointing to active distribution as the rally faded.
What Drove NVAX Stock Performance Over the Last Quarter
Across the full quarter, NVAX displayed a classic round-trip pattern: a sharp rally in late September and early October, followed by a retracement that left the stock only modestly higher. The earlier strength reflected renewed interest in vaccine names and a generally improving tone for the biotech sector, while the subsequent pullback highlighted how quickly sentiment-driven gains can reverse in the absence of sustained fundamental confirmation.
The broader narrative remains one of a company in transition. Novavax continues to pivot from pandemic-era COVID-19 revenue toward a more diversified vaccine portfolio, and investors have remained cautious about how quickly those new programs can translate into durable revenue growth.
NVAX Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape NVAX's trajectory going forward. Quarterly earnings and management guidance will remain central, particularly any updates on COVID-19 vaccine revenue and the pace of cash burn. Progress on the COVID-influenza combination vaccine program and the stand-alone influenza candidate will be closely watched, as pipeline milestones could meaningfully shift the company's long-term revenue outlook.
Beyond company-specific developments, seasonal vaccine demand, competition from mRNA-based rivals, and the broader environment for biotechnology financing and risk appetite will all influence sentiment. As a historically volatile stock, NVAX remains sensitive to shifts in sector momentum, making both its fundamentals and the wider market backdrop important variables for investors to monitor. From what I see, this is important because it underscores the need for ongoing vigilance in this name.
Exploring Tickeron AI Tools for Deeper Insights
In my analysis of names like NVAX, I often turn to Tickeron’s platform to cross-check patterns and signals. The Trending AI Robots section highlights some of the platform’s strongest automated strategies, which monitor thousands of tickers and surface only the most relevant performers. These tools provide a useful layer of data-driven perspective that can complement traditional research, especially when evaluating volatility in biotech names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
NVAX in +11.35% Uptrend, rising for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVAX advanced for three days, in 192 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
NVAX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NVAX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.324) is normal, around the industry mean (3.498). P/E Ratio (-7.046) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology